Phospho-CDK4 (Thr172) Antibody - #AF8007

>>赠JD卡 进行中>>
(2)   (11)  
产品: 磷酸化 CDK4 (Thr172) 抗体
货号: AF8007
描述: Rabbit polyclonal antibody to Phospho-CDK4 (Thr172)
应用: WB IHC IF/ICC
文献验证: WB
反应: Human, Mouse, Rat
预测: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Xenopus
蛋白号: P11802
RRID: AB_2840070

浏览相似产品>>

   规格 价格 库存
 100ul RMB¥ 2800 现货
 200ul RMB¥ 3800 现货

货期: 当天发货

联系销售
相关下载
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
IF/ICC 1:100-1:500, WB 1:1000-3000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Phospho-CDK4 (Thr172) Antibody detects endogenous levels of CDK4 only when phosphorylated at Thr172.
RRID:
AB_2840070
引用格式: Affinity Biosciences Cat# AF8007, RRID:AB_2840070.
偶联:
Unconjugated.
纯化:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Cdk 4; cdk4; CDK4 protein; CDK4_HUMAN; Cell division kinase 4; Cell division protein kinase 4; CMM 3; CMM3; Crk3; Cyclin dependent kinase 4; Cyclin-dependent kinase 4; Melanoma cutaneous malignant 3; MGC14458; p34 cdk4; PSK J3; PSK-J3;

抗原和靶标

免疫原:

A synthesized peptide derived from human CDK4 around the phosphorylation site of Thr172.

基因/基因ID:
CDK4(1019)

研究领域

· Cellular Processes > Cell growth and death > Cell cycle.   (View pathway)

· Cellular Processes > Cell growth and death > p53 signaling pathway.   (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Tight junction.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

文献引用

1). 2,3,7,8-Tetrachlorodibenzo-p-dioxin promotes injury-induced vascular neointima formation in mice. FASEB JOURNAL, 2019 (PubMed: 31216422) [IF=4.4]

Application: WB    Species: human    Sample: VSMCs

Figure 2.| TCDD treatment promotes VSMC proliferation in vitro. A) Cell cycle of VSMCs treated with TCDD was analyzed by FACS. B) Cell population in G0/G1, S, and G2/M phases was quantified. *P ,0.05 vs. vehicle (n = 4). C)The mRNA levels of PCNA,cyclin D1, and CDK4 in TCDDtreated VSMCs were determined by RT-PCR. *P , 0.05vs. vehicle (n = 5). D) PCNA,cyclin D1 TCDD-treated VSMCs were analyzed by Western blot. E) Western blot analysis of the phosphorylation of CDK4(Thr172) (p-CDK4) and the expression of total CDK4 (TCDK4). F) The expression of pCDK4 was quantified. *P , 0.05 vs. vehicle (n = 3).
2). Aaptamine attenuates the proliferation and progression of non-small cell lung carcinoma. PHARMACEUTICAL BIOLOGY, 2020 (PubMed: 33027592) [IF=3.9]

Application: WB    Species: human    Sample: A549 and H1299 cells

Figure 4. |Aaptamine balks cell cycle progression of NSCLC cells. s (C) and immunoblotting assay (D and E) of A549 and H1299 cells treated with aaptamine (0, 8, 16 and 32 lg/mL), respectively, for 48 h with densitometric analysis showing that aaptamine could decrease the mRNA and protein level of cell cycle-specific driver kinases in a dose-dependent manner. p < 0.05, p < 0.01 and p < 0.001 vs. untreated control.

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.